CA2668320A1 - Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel - Google Patents

Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel Download PDF

Info

Publication number
CA2668320A1
CA2668320A1 CA002668320A CA2668320A CA2668320A1 CA 2668320 A1 CA2668320 A1 CA 2668320A1 CA 002668320 A CA002668320 A CA 002668320A CA 2668320 A CA2668320 A CA 2668320A CA 2668320 A1 CA2668320 A1 CA 2668320A1
Authority
CA
Canada
Prior art keywords
androstanediol
alpha
sexual dysfunction
ht1a agonist
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002668320A
Other languages
English (en)
Other versions
CA2668320C (fr
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Robertus Petrus Johannes De Lange
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emotional Brain BV
Original Assignee
Emotional Brain B.V.
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Robertus Petrus Johannes De Lange
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emotional Brain B.V., Jan Johan Adriaan Tuiten, Johannes Martinus Maria Bloemers, Robertus Petrus Johannes De Lange filed Critical Emotional Brain B.V.
Publication of CA2668320A1 publication Critical patent/CA2668320A1/fr
Application granted granted Critical
Publication of CA2668320C publication Critical patent/CA2668320C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
CA2668320A 2006-11-03 2007-11-02 Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel Expired - Fee Related CA2668320C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06076976.7 2006-11-03
EP06076976A EP1925307A1 (fr) 2006-11-03 2006-11-03 Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
PCT/NL2007/050535 WO2008054215A2 (fr) 2006-11-03 2007-11-02 Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel

Publications (2)

Publication Number Publication Date
CA2668320A1 true CA2668320A1 (fr) 2008-05-08
CA2668320C CA2668320C (fr) 2014-06-10

Family

ID=37846101

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2668317A Expired - Fee Related CA2668317C (fr) 2006-11-03 2007-11-02 Utilisation de 3-alpha-androstanediol eventuellement combine a un inhibiteur de la pde5, dans le traitement d'un dysfonctionnement sexuel
CA2668320A Expired - Fee Related CA2668320C (fr) 2006-11-03 2007-11-02 Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel
CA2668316A Active CA2668316C (fr) 2006-11-03 2007-11-02 Utilisation de testosterone et d'un agoniste de la 5-ht1a dans le traitement d'un dysfonctionnement sexuel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2668317A Expired - Fee Related CA2668317C (fr) 2006-11-03 2007-11-02 Utilisation de 3-alpha-androstanediol eventuellement combine a un inhibiteur de la pde5, dans le traitement d'un dysfonctionnement sexuel

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2668316A Active CA2668316C (fr) 2006-11-03 2007-11-02 Utilisation de testosterone et d'un agoniste de la 5-ht1a dans le traitement d'un dysfonctionnement sexuel

Country Status (28)

Country Link
US (10) US8653051B2 (fr)
EP (5) EP1925307A1 (fr)
JP (8) JP2010509211A (fr)
KR (6) KR20090115113A (fr)
CN (6) CN104524580A (fr)
AU (3) AU2007314735B2 (fr)
BR (3) BRPI0717963A2 (fr)
CA (3) CA2668317C (fr)
CY (1) CY1117191T1 (fr)
DK (1) DK2086544T3 (fr)
ES (1) ES2561946T3 (fr)
HK (1) HK1135038A1 (fr)
HR (1) HRP20160108T1 (fr)
HU (1) HUE026752T2 (fr)
IL (5) IL198460A (fr)
ME (1) ME02410B (fr)
MX (3) MX2009004696A (fr)
NO (3) NO343597B1 (fr)
NZ (3) NZ577390A (fr)
PH (2) PH12014501440A1 (fr)
PL (1) PL2086544T3 (fr)
PT (1) PT2086544E (fr)
RS (1) RS54541B1 (fr)
RU (4) RU2491073C2 (fr)
SI (1) SI2086544T1 (fr)
UA (4) UA103592C2 (fr)
WO (3) WO2008054215A2 (fr)
ZA (3) ZA200903835B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2436579C2 (ru) 2004-05-11 2011-12-20 Эмоушнл Брэйн Б.В. Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции
EP1790343A1 (fr) * 2005-11-11 2007-05-30 Emotional Brain B.V. Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
EP1925307A1 (fr) 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
EP2266568A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel
EP2266567A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel
KR102158948B1 (ko) * 2011-05-13 2020-09-24 이비 아이피 하이브리탭스 비.브이. 약물 전달 시스템
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (ja) 2014-01-30 2015-12-09 国立大学法人高知大学 ニッケル粉の製造方法
US10471514B2 (en) 2014-02-21 2019-11-12 Kochi University, National University Corporation Method for producing nickel powder
JP6406613B2 (ja) 2014-04-15 2018-10-17 住友金属鉱山株式会社 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法
CN103947533B (zh) * 2014-05-15 2015-12-16 青岛理工大学 生长环境可控的磁化水工厂化豆芽菜生产系统
RU2600845C2 (ru) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DK169601B1 (da) * 1983-10-17 1994-12-19 Duphar Int Res Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (fr) * 1989-02-27 1995-04-04 John Mehnert Schaus 2-amino-1,2,3,4-tetrahydronaphtalenes a substituants sur le cycle
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
US6174890B1 (en) 1994-06-02 2001-01-16 Dan Riga Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
US5698560A (en) 1995-03-01 1997-12-16 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
CZ278497A3 (cs) 1995-03-14 1998-04-15 Vivus, Incorporated Způsob a sestava zařízení k prevenci impotence
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2219082A1 (fr) 1995-05-15 1996-11-21 Beth Israel Deaconess Medical Center, Inc. Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
AU756136B2 (en) * 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
JP2001520999A (ja) 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6246436B1 (en) * 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
EP1173167A4 (fr) 1999-04-30 2004-07-14 Lilly Icos Llc Traitement des troubles de la stimulation sexuelle feminine
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
CA2377339A1 (fr) 1999-06-17 2000-12-28 Armin Johannes Becker Utilisation d'hormone de croissance (hgh) pour traiter les troubles de la fonction sexuelle
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) * 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CN1473047A (zh) 2000-08-30 2004-02-04 ������ҩ�����޹�˾ 治疗男性勃起功能障碍和增强性冲动的方法
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
SK287066B6 (sk) 2000-09-29 2009-11-05 Solvay Pharmaceuticals B. V. Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
JP2004522720A (ja) * 2000-12-15 2004-07-29 ファイザー・インク 雄性性的機能障害の処置
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
EP1383502A4 (fr) 2001-03-06 2007-07-25 Strakan Int Ltd Composes et procedes pour le traitement de desordres urogenitaux
EA006154B1 (ru) 2001-03-28 2005-10-27 Пфайзер Инк. N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad
EP1260225A1 (fr) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
JP2007516949A (ja) * 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
WO2005094827A1 (fr) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methodes de traitement d'un dysfonctionnement sexuel
RU2445095C2 (ru) 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые фармацевтические композиции для лечения сексуальных расстройств
RU2436579C2 (ru) * 2004-05-11 2011-12-20 Эмоушнл Брэйн Б.В. Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции
KR20080016552A (ko) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
WO2006127057A1 (fr) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel
WO2006125642A1 (fr) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Procedes et dispositifs d'application transdermique ou transmucosale de testosterone
WO2007054791A2 (fr) 2005-11-08 2007-05-18 L'oréal Glucuronides androgenes en tant que marqueurs d’activite androgenique
EP1790343A1 (fr) 2005-11-11 2007-05-30 Emotional Brain B.V. Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
EP1925307A1 (fr) 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
KR101694551B1 (ko) 2007-11-28 2017-01-09 유씨비 파마 게엠베하 로티고틴의 다형 형태

Also Published As

Publication number Publication date
US8669242B2 (en) 2014-03-11
RU2009120990A (ru) 2010-12-10
JP2010509211A (ja) 2010-03-25
EP2086544B1 (fr) 2015-12-23
IL248563B (en) 2018-11-29
US8653051B2 (en) 2014-02-18
US8575139B2 (en) 2013-11-05
AU2007314736B2 (en) 2014-01-23
KR20150038251A (ko) 2015-04-08
IL198461A (en) 2017-08-31
HRP20160108T1 (hr) 2016-03-25
CA2668316A1 (fr) 2008-05-08
KR20090111803A (ko) 2009-10-27
KR101578224B1 (ko) 2015-12-16
RS54541B1 (en) 2016-06-30
RU2009120988A (ru) 2010-12-10
RU2012125827A (ru) 2013-12-27
JP6357131B2 (ja) 2018-07-11
MX2009004696A (es) 2009-06-05
CA2668317C (fr) 2016-02-09
KR20090115113A (ko) 2009-11-04
HUE026752T2 (en) 2016-07-28
JP2010509212A (ja) 2010-03-25
CN101557812A (zh) 2009-10-14
JP2017132809A (ja) 2017-08-03
US9211334B2 (en) 2015-12-15
IL237786A0 (en) 2015-05-31
JP2010509213A (ja) 2010-03-25
ZA200903835B (en) 2010-10-27
WO2008054215A2 (fr) 2008-05-08
CN101573119A (zh) 2009-11-04
BRPI0717856A2 (pt) 2013-10-29
US9597335B2 (en) 2017-03-21
JP2015157849A (ja) 2015-09-03
EP2937086A1 (fr) 2015-10-28
US20140038929A1 (en) 2014-02-06
WO2008054214A2 (fr) 2008-05-08
CA2668320C (fr) 2014-06-10
US20100093680A1 (en) 2010-04-15
AU2007314736A1 (en) 2008-05-08
IL198460A (en) 2016-11-30
JP2014111608A (ja) 2014-06-19
UA115647C2 (uk) 2017-12-11
US20160082018A1 (en) 2016-03-24
WO2008054213A2 (fr) 2008-05-08
RU2463054C2 (ru) 2012-10-10
RU2491073C2 (ru) 2013-08-27
KR20150099620A (ko) 2015-08-31
CN103381270A (zh) 2013-11-06
US20170157142A1 (en) 2017-06-08
EP2086544A2 (fr) 2009-08-12
PT2086544E (pt) 2016-03-17
KR20160124246A (ko) 2016-10-26
SI2086544T1 (sl) 2016-04-29
IL198459A0 (en) 2010-02-17
AU2007314734B2 (en) 2014-01-30
MX2009004695A (es) 2009-06-05
PL2086544T3 (pl) 2016-07-29
NZ577390A (en) 2012-12-21
US20190262359A1 (en) 2019-08-29
ZA200903837B (en) 2010-08-25
IL198459A (en) 2016-11-30
ZA200903836B (en) 2010-08-25
KR20090111802A (ko) 2009-10-27
AU2007314735A1 (en) 2008-05-08
AU2007314734A1 (en) 2008-05-08
PH12014501821A1 (en) 2016-02-01
NO20092143L (no) 2009-07-02
WO2008054214A3 (fr) 2009-04-09
NZ577393A (en) 2012-11-30
CA2668316C (fr) 2014-06-10
BRPI0718396A2 (pt) 2013-11-26
EP1925307A1 (fr) 2008-05-28
UA103592C2 (uk) 2013-11-11
NO20092146L (no) 2009-07-21
JP2014001235A (ja) 2014-01-09
NZ577392A (en) 2012-11-30
CN103599536A (zh) 2014-02-26
DK2086544T3 (en) 2016-02-08
CN104524580A (zh) 2015-04-22
ME02410B (fr) 2016-09-20
WO2008054215A3 (fr) 2009-04-09
IL198461A0 (en) 2010-02-17
KR101796887B1 (ko) 2017-11-10
US20140121190A1 (en) 2014-05-01
CY1117191T1 (el) 2017-04-05
US20100160270A1 (en) 2010-06-24
UA101948C2 (uk) 2013-05-27
EP2086545A2 (fr) 2009-08-12
US20120277200A1 (en) 2012-11-01
US20140121189A1 (en) 2014-05-01
MX2009004693A (es) 2009-06-05
RU2646447C2 (ru) 2018-03-05
UA100119C2 (uk) 2012-11-26
US10314848B2 (en) 2019-06-11
US20100152145A1 (en) 2010-06-17
IL198460A0 (en) 2010-02-17
CN101563086B (zh) 2013-11-27
EP2086548A2 (fr) 2009-08-12
IL248563A0 (en) 2016-12-29
JP2014055142A (ja) 2014-03-27
AU2007314735B2 (en) 2014-01-16
CN101563086A (zh) 2009-10-21
HK1135038A1 (en) 2010-05-28
BRPI0717963A2 (pt) 2013-11-05
PH12014501821B1 (en) 2016-02-01
ES2561946T3 (es) 2016-03-01
JP5748238B2 (ja) 2015-07-15
NO343597B1 (no) 2019-04-08
RU2464027C2 (ru) 2012-10-20
WO2008054213A3 (fr) 2009-04-09
PH12014501440A1 (en) 2016-02-01
US8648060B2 (en) 2014-02-11
NO20092145L (no) 2009-07-21
RU2009120992A (ru) 2010-12-10
CA2668317A1 (fr) 2008-05-08

Similar Documents

Publication Publication Date Title
CA2668320A1 (fr) Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel
NO20090610L (no) Faste preparater omfattende tadalafil og minst en baerer
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2007146124A3 (fr) Inhibiteurs de pde5 substitué
WO2005107810A3 (fr) Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
MY143795A (en) Tetrahydropyridoindole derivatives
WO2004074266A8 (fr) 1,2,4-triazines inhibant le vih
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2006116148A3 (fr) Traitement de l'abus de substances toxiques
WO2005102392A3 (fr) Methodes de traitement d'une infection a vih
WO2004030611A3 (fr) Inhibiteurs non nucleosidiques de transcriptases inverses
WO2007103200A3 (fr) Formulation orale à libération contrôlée pour des agents sédatifs ou hypnotiques
EP1993567A4 (fr) Préparations de gallium administrables per os et leurs méthodes d'utilisation
EP2033954A4 (fr) Composé 6-(benzyle substituté par hétérocycle)-4-oxoquinoline et utilisation de celui-ci comme inhibiteur de l'intégrase du vih
WO2008116890A3 (fr) Nouvelles compositions pharmaceutiques
WO2008026156A3 (fr) Compositions therapeutiques
WO2008023362A3 (fr) Traitement du cancer
WO2005082413A3 (fr) Combinaison de ciclesonide et de glycopyrronium
WO2004071374A3 (fr) Compositions pharmaceutiques d'administration orale une fois par jour
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2008136034A3 (fr) Compositions ophtalmiques pour le traitement d'une hypertension oculaire et d'un glaucome
WO2007010501A3 (fr) Composition pharmaceutique comprenant une combinaison d'un beta-bloquant et d'un inhibiteur d'ace
WO2006063596A8 (fr) Composition renfermant des polypeptides pancreatiques pour le traitement de troubles gastrointestinaux
WO2007022532A3 (fr) Composes cyclopropyles et compositions permettant de liberer des agents actifs

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191104